获利能力 Profitability (单位:美元)
| 指标 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| 净资产收益率(ROE) | 7.71% | 11.97% | 14.08% | 20.62% | 19.13% | 15.20% | 31.07% | 13.07% |
| 总资产收益率(ROA) | 3.53% | 5.43% | 6.20% | 9.40% | 9.31% | 7.82% | 16.46% | 7.52% |
| 毛利率 | 58.45% | 58.53% | 56.65% | 56.97% | 56.15% | 55.18% | 55.41% | 56.42% |
| 净利率 | 7.74% | 11.56% | 12.99% | 16.42% | 15.88% | 14.27% | 31.95% | 14.72% |
| 每股收益(EPS) | 1.34 | 2.07 | 2.52 | 3.97 | 3.94 | 3.28 | 7.67 | 3.73 |
财务结构 Financial Structure
| 指标 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| 现金占总资产比率 | 5.72% | 5.69% | 9.43% | 13.03% | 13.28% | 9.42% | 9.35% | 9.83% |
| 负债占总资产比率 | 54.26% | 53.89% | 54.51% | 52.09% | 50.42% | 46.97% | 41.16% | 39.14% |
经营能力 Operating Capability
| 指标 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| 应收账款周转率(次) | 5.90 | 5.88 | 5.40 | 6.64 | 7.02 | 6.11 | 6.06 | 5.59 |
| 平均收现日数 | 62 天 | 62 天 | 68 天 | 55 天 | 52 天 | 60 天 | 60 天 | 65 天 |
| 固定资产周转率(次) | 0.4680 | 0.4755 | 0.4883 | 0.4193 | 0.4290 | 0.4954 | 0.4828 | 0.5690 |
| 总资产周转率 | 45.52% | 47.00% | 47.70% | 57.28% | 58.64% | 54.78% | 51.53% | 51.12% |
现金流量 Cash Flow (单位:亿美元)
| 指标 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| 现金及现金等价物 | 38.44 | 38.60 | 68.38 | 97.99 | 98.82 | 68.96 | 76.16 | 85.22 |
| 净利润 | 23.68 | 36.87 | 44.95 | 70.71 | 69.33 | 57.23 | 134.02 | 65.24 |
| 经营活动现金流量 | 63.00 | 61.36 | 79.01 | 105.33 | 95.81 | 72.61 | 85.58 | 95.66 |
| 投资活动现金流量 | -13.56 | -18.15 | -22.15 | -20.08 | -17.40 | -31.33 | -23.38 | -24.22 |
| 筹资活动现金流量 | -103.91 | -42.89 | -27.79 | -54.94 | -76.36 | -70.91 | -54.04 | -63.09 |
| 净现金流量 | -55.63 | 0.16 | 29.78 | 29.61 | 0.83 | -29.86 | 7.20 | 9.06 |
医疗保健
- 近五年ROE对比
1
100.00%
PACS Group Inc
PACS
2
100.00%
ImmunityBio Inc
亏损年份
IBRX
3
100.00%
安进
AMGN
4
100.00%
奥洛兹美医疗
HALO
5
100.00%
Puma Biotechnology Inc
亏损年份
PBYI
6
100.00%
沃特世
WAT
7
100.00%
Picard Medical Inc
数据<5年
亏损年份
PMI
8
84.37%
IDEXX实验室
IDXX
9
79.94%
泰尼特保健
THC
10
74.93%
礼来
LLY
11
74.56%
诺和诺德
NVO
12
62.37%
BridgeBio Pharma Inc
亏损年份
BBIO
13
52.47%
硕腾
ZTS
14
50.94%
NRC Health
NRC
15
49.16%
Medpace Holdings Inc
MEDP
16
48.89%
葛兰素史克
GSK
17
32.44%
Harmony Biosciences Holdings In
HRMY
18
32.16%
Innoviva Inc
INVA
19
31.55%
强生
JNJ
20
30.84%
默沙东
MRK
21
30.27%
Chemed Corp
CHE
22
29.98%
InMode Ltd
INMD
23
28.48%
西佳科技
SIGA
24
27.65%
爱德华兹生命科学
EW
25
26.99%
诺华制药
NVS
26
25.87%
Catalyst Pharmaceuticals Inc
CPRX
27
25.81%
吉利德科学
GILD
28
24.45%
再生元制药
REGN
29
23.09%
德康医疗
DXCM
30
23.02%
瑞思迈
RMD
31
19.82%
雅培
ABT